STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #984 by analyst upside · 2026-08-14
TNGX
Tango Therapeutics, Inc.
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+73.8%
implied upside to consensus target
Current Price $25.65
Consensus Target $44.58
Bull Target $69.0
Bear Target $24.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
10
Hold
1
Sell
0
52-Week Low $6.25
52-Week High $34.39
YTD Return +187.2%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.84
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $54M
Profit Margin -229.9%
52-WEEK RANGE
52-Week Low $6.25
52-Week High $34.39
Current Price $25.65
Bear Target $24.0
Bull Target $69.0
● Now $25.65 ● Target $44.58
TRADING DATA
Avg Volume 4.0M
YTD Return +187.2%
Analyst Count 12
Consensus Buy
Upside to Target +73.8%
Last Updated 2026-08-14

ANALYST SUMMARY

Tango Therapeutics, Inc. (TNGX) is currently trading at $25.65 with a Wall Street consensus price target of $44.58, implying potential upside of 73.8% over the next 12 months. 12 analysts currently cover TNGX, with a consensus rating of Buy - 92% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $69.0, while the most cautious has a target of $24.0.

TNGX operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 187.2% year-to-date and is currently trading near the upper end of its 52-week range of $6.25 – $34.39.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TNGX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity - Reiterated
Buy → Buy 2026-06-11 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-06-09 31% win rate (48 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2026-06-09 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-06-08 29% win rate (7 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-05-15 Building track record
Piper Sandler ↓ Downgrade
Overweight → Neutral 2026-05-15 14% win rate (7 calls)
Jefferies ↓ Downgrade
Buy → Hold 2026-05-14 50% win rate (6 calls)
Leerink Partners - Reiterated
Outperform → Outperform 2026-05-14 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
42
out of 100
Coverage depth
20/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →